MABIMMUNE
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment. The company was founded in 2013 and is headquartered in Schlieren, Zurich.
MABIMMUNE
Industry:
Health Care Health Diagnostics Medical
Founded:
2013-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.mabimmune.com
Total Employee:
1+
Status:
Active
Total Funding:
130 K CHF
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Metabolomic Diagnostics
Metabolomic Diagnostics specializes in the development of novel biomarker based diagnostic solutions for complex diseases
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Founder
Investors List
Venture Kick
Venture Kick investment in Pre Seed Round - Mabimmune
Venture Kick
Venture Kick investment in Grant - Mabimmune
Venture Kick
Venture Kick investment in Grant - Mabimmune
More informations about "Mabimmune" on Search Engine
Mabimmune Company Profile: Valuation, Funding
May 1, 2015 Description. Provider of therapeutic services intended to treat patients with solid tumors. The company's services aim to develop immunotherapeutics with best-in …See details»
Mabimmune Diagnostics AG | VentureRadar
Founded in 2013. Private Company. Develops immune agonists using Reverse Translational Medicine platform to create human monoclonal antibodies targeting tumor …See details»
Mabimmune AG (merged with Neurimmune) - Venturelab
Mabimmune AG (merged with Neurimmune): Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off …See details»
Mabimmune AG (merged with Neurimmune) - startup.ch
Mabimmune AG (merged with Neurimmune) Developing immune agonists with best-in-class therapeutic indices. Website: www.mabimmune.com. Headquarter: Schlieren …See details»
Mabimmune - Funding, Financials, Valuation & Investors …
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment.See details»
Mabimmune Therapeutics AG | VentureRadar
Mabimmune aims to prevent myocardial infarction and stroke through early diagnosis and targeted treatment. The Product – Mabimmune’s InfarctPrevent... ... Find out more …See details»
Mabimmune AG (merged with Neurimmune) - top100startup.ch
Mabimmune AG (merged with Neurimmune): Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off …See details»
mabimmune Company Profile: Funding, Investors & Partnerships
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment.See details»
Mabimmune AG (merged with Neurimmune) - Venture Kick
Mabimmune is developing immune agonists from the RTM platform designed to offer best-in-class therapeutic indices. News 25.08.2022 "Innovation needs diversity" — Interview …See details»
Mabimmune AG: Drug pipelines, Patents, Clinical trials - Synapse
Explore Mabimmune AG with its drug pipeline, therapeutic area, technology platform, .See details»
Mabimmune - Tech Stack, Apps, Patents & Trademarks
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment.See details»
mabimmune - Patents
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment.See details»
SGN-B7H4V, an investigational vedotin ADC directed to the …
Background SGN-B7H4V is a novel investigational vedotin antibody–drug conjugate (ADC) comprising a B7-H4-directed human monoclonal antibody conjugated to the cytotoxic …See details»
Mabimmune Diagnostics AG - life-sciences-europe.com
Jan 1, 2011 Upcoming Events. AACR Annual Meeting 2024 San Diego; ENC Conference 2024 Pacific Grove; Analytica 2024 München (Munich) SynBee Day 2024 Brussels; …See details»
Canadian Trademarks Details: Mabimmune — 1410957 — …
Mabimmune Diagnostics AG. c/o Neurimmune Holding AG. Wagistrasse 13. 8952 Schlieren. SWITZERLAND. Agent. GOWLING WLG (CANADA) LLP. SUITE 1600. 1 …See details»
Mabimmune AG, Schlieren, Switzerland - North Data
Mabimmune Holding AG. Register. Ktreg. Schweizer Handelsregister CHE-115.895.111. Address. Schlieren, Switzerland. Corporate purpose. The aim of the society is to …See details»
MedImmune Joins Forces With Leading Cancer Organizations to …
Oct 9, 2012 NEW YORK and GAITHERSBURG, Md., Oct. 9, 2012 /PRNewswire/ -- The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and …See details»
RTM™ Technology Platform – Neurimmune
Reverse Translational Medicineâ„¢ (RTMâ„¢) is Neurimmune’s proprietary technology platform. It is based on the scientific understanding and high-throughput analyses of …See details»
Chad Brokopp - Crunchbase Person Profile
Number of Founded Organizations 1. CB Rank (Person) 94,124. Location Zürich, Zurich, Switzerland. Regions Europe, Middle East, and Africa (EMEA) Gender Male. LinkedIn …See details»
Mabimmune - Crunchbase
Organization. Mabimmune . Connect to CRM . Save . Summary Financials People Technology Signals & News Similar Companies. Similar Companies. Edit Similar …See details»